Turn Therapeutics Inc. (TTRX)
Turn Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
Turn Therapeutics is a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance.
Our patented mixing process — commercially referred to as PermaFusion — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.
This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.
Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis.
Turn Therapeutics Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Bradley Burnam |
Contact Details
Address: 250 N. Westlake Blvd. Westlake Village, CA 91362 United States | |
| Phone | (818) 564-4011 |
| Website | turntherapeutics.com |
Stock Details
| Ticker Symbol | TTRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002023016 |
| Employer ID | 32-0456090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bradley Burnam | Chief Executive Officer & Director |
| Zuraiz Chaudhary | Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer |
| Dr. Neil Ghodadra | Chief Medical Officer & Director |
| Andrew Gengos | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 2, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 30, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 27, 2025 | 1-K | Acc-no: 0001493152-22-011625 (33 Act) |
| Jun 20, 2025 | DRS | [Cover] Draft Registration Statement |
| Jun 13, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Apr 29, 2025 | C-AR | Filing |
| Apr 22, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Apr 2, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Mar 31, 2025 | QUALIF | Filing |
| Mar 27, 2025 | 1-A/A | Filing |